drugset / Trial / NCT00269750

A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.

NCT00269750

Phase 3 Completed 100 enrolled Alza Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.

Timeline

Start
1996-07
Primary completion
Completion
1997-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 5 mg Oral
Subject Oxybutynin Small molecule 10 mg Oral
Subject Oxybutynin Small molecule 15 mg Oral
Subject Oxybutynin Small molecule 20 mg Oral
Subject Oxybutynin Small molecule 25 mg Oral
Subject Oxybutynin Small molecule 30 mg Oral